FDA Approves Xarelto To Reduce Risk Of Blood Clots
On July 1, the U.S. Food and Drug Administration approved Xarelto ( rivaroxaban ) to reduce the risk of blood clots, deep vein thrombosis ( DVT ), and pulmonary embolism (PE) following knee or hip replacement surgery.